Donghui Liu

South China University of Technology

Donghui Liu received his M.D. degree from Hebei Medical University, China, in 2002. And he obtained Ph.D. degree from the Physiology and Pathophysiology Department, Peking University, China, in 2011. From 2011 to 2018, he worked in the Department of Cardiology, the affiliated Cardiovascular Hospital of Xiamen University, China. Then he worked in the Department of Cardiology, Fujian Provincial Hospital, Provincial Clinical Medicine College of Fujian Medical University, China, from 2019 to 2020. In 2021, as the Associate Professor and the Associate Director, he joined in the Department of Geriatrics, National Key Clinic Specialty, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, China. His general research interests are in the area of dyslipidemia, atherosclerotic cardiovascular disease, heart failure, metabolomics and organ rehabilitation in elderly patients.

1chapters authored

Latest work with IntechOpen by Donghui Liu

Statins are now the most widely used agents in patients with dyslipidemia, atherosclerosis and cardiovascular disease. However, their effects and mechanisms have not been fully investigated, and research continues to reveal new aspects of statins. The up-to-date content of this book will be useful to physicians in cardiovascular disease and geriatrics, and to academics conducting research on statins. It includes novel perspectives leading to new insights and advancing existing knowledge on statins.

Go to the book

Statins

Edited by Donghui Liu

Chapters authored

High-Density Lipoprotein: From Biological Functions to Clinical Perspectives

By Donghui Liu

High-density lipoprotein (HDL) is a heterogeneous particle composed of apolipoproteins, enzymes, and lipids. Besides transporting cholesterol to the liver, HDL also exerts many protections on anti-oxidation, anti-inflammation, and anti-apoptosis. Initial understandings of HDL came from its protective roles against atherosclerosis and the observation that high plasma HDL cholesterol (HDL-C) levels seemed to decrease cardiovascular disease (CVD) attack. However, those patients either with cholesterol ester transfer protein (CETP) deficiency or taking CETP inhibitors substantially elevated HDL-C levels but did not necessarily decrease CVD risk. Thus, some researchers suggested that quantitative measurements of HDL particle (HDL-P) might be more valuable than traditional HDL-C measurements. What is more bewildering is that HDL from patients with systemic inflammation decreased its protective effects and even became a pro-inflammatory factor. Recently, synthesized HDL and apolipoprotein mimetic peptides showed biological functions similar to native ones. Expectedly, lots of novel measurement methods and therapeutic agents about HDL would be established soon.

Part of the book: Apolipoproteins, Triglycerides and Cholesterol

Donghui Liu

Latest work with IntechOpen by Donghui Liu

Statins

Chapters authored

Related collaborators

Rafael Burgos

María A. Hidalgo

David Coman

Suzanne Sindi

Mikahl Banwarth-Kuhn

Jie Lin

Vinayak Uppin

Ramaprasad Talahalli

Pooja Acharya

Marcelo Ratto